<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Chase Finnegan | Activity</title>
	<link>https://www.catswannabecats.com/members/orchidpatio6/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/orchidpatio6/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Chase Finnegan.</description>
	<lastBuildDate>Sat, 04 Jul 2026 08:03:39 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">3f1826c6e89af2a28638131b5de1b2f3</guid>
				<title>Chase Finnegan posted an update: Vessel size, location and time between injury and diagnosis [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/12152/</link>
				<pubDate>Sun, 01 Jun 2025 08:53:10 -0400</pubDate>

									<content:encoded><![CDATA[<p>Vessel size, location and time between injury and diagnosis made endovascular intervention impractical. The patient was started on aspirin and Plavix, observed for 3 days and sent home.</p>
<p> Once a patent expires, generic analogue drugs are alternatives to brand name drugs. Because bioequivalence/biodistribution problems have been reported for m&hellip;<span class="activity-read-more" id="activity-read-more-12152"><a href="https://www.catswannabecats.com/activity/p/12152/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">474c85d29befc910e97d82ae32c45adb</guid>
				<title>Chase Finnegan posted an update: Anti-epidermal growth factor receptor (EGFR) monoclonal [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/4156/</link>
				<pubDate>Sat, 31 May 2025 12:14:36 -0400</pubDate>

									<content:encoded><![CDATA[<p>Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab or panitumumab) are today increasingly used in the first- or second-line setting for RAS wild-type metastatic colorectal cancer (CRC) patients. Following progression beyond third- or fourth-line therapy, some patients are unsuitable for further chemotherapy because of&hellip;<span class="activity-read-more" id="activity-read-more-4156"><a href="https://www.catswannabecats.com/activity/p/4156/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">62251f86307e2b6fead68710e7a9245e</guid>
				<title>Chase Finnegan became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/4046/</link>
				<pubDate>Sat, 31 May 2025 11:59:36 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>